Electronucleics

Electronucleics Inc. is a medical technology company developing a low-cost, point-of-care diagnostic device designed for the rapid detection of pathogens. Utilizing an optics-free, non-amplification electromechanical signal transduction mechanism, the device identifies target nucleic acids through pore blockades. By bypassing traditional laboratory processes like polymerase chain reaction (PCR) or culturing, the technology is engineered to provide highly selective, binary test results in approximately 10 minutes. The platform relies on a simple, robust design featuring a base unit and disposable cartridges, allowing for significant miniaturization of diagnostic capabilities originally developed at UCLA.

The company aims to address the critical need for immediate clinical diagnostics, enabling healthcare providers to diagnose and treat conditions such as chlamydia, gonorrhea, and human papillomavirus during a single patient visit. By offering a rapid, inexpensive, and accurate alternative to centralized lab testing, Electronucleics seeks to improve patient outcomes and increase access to essential healthcare. The company, which is privately held and based in Placentia, California, has been supported by federal research grants, including those from the National Institutes of Health (NIH), to advance the clinical validation and engineering of its diagnostic prototypes.